deltatrials
Not Yet Recruiting PHASE2 INTERVENTIONAL 2-arm NCT06933966

Evaluation of Efficacy and Safety De-escalation Versus Standard Adjuvant Chemotherapy in Patients With Low Risk Localized Gastroesophageal Adenocarcinoma (ATTENUATION)

ATTENUATION - A Multicenter Randomized Phase II Study of the Efficacy and Safety De-escalation Versus Standard Adjuvant Chemotherapy in Patients With Low Risk Localized Gastroesophageal Adenocarcinoma (PRODIGE99/FRENCH 39 Study)

Sponsor: Centre Leon Berard

Conditions Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma Non Metastatic Disease
Interventions observation alone
Updated 1 time since 2025 Last updated: Apr 16, 2025 Started: Sep 1, 2025 Primary completion: Sep 1, 2030 Completion: Sep 1, 2032
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma and Non Metastatic Disease and is currently actively recruiting participants. Centre Leon Berard leads this study, which shows 1 recorded version since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~May 2025 – present · 14 months · monthly snapshotNot Yet Recruiting

Change History

1 version recorded
Not Yet Recruiting — PHASE2 [monthly]

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Centre Leon Berard
Data source: Centre Leon Berard

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations